plications were among the secondary end-points. The majority of patients (>60%) were included because of The renin-angiotensin system (RAS ) is well known evidence of coronary heart disease, >25% because of for its role in blood pressure and electrolyte and diabetes plus one other risk factor and the rest (about volume homeostasis. Experimental evidence from 10%) because of peripheral vascular disease or stroke. recent years linked the RAS with inflammatory pro-
The active treatment was added to any other drugs the cesses; the stimulation of interstitial fibrosis and of patient needed. At the end of the trial, about 80% of mesangial sclerosis may be taken as examples in nephthe patients were on antiplatelet drugs and about rology [1, 2] . In a more general perspective, the RAS 40-50% each on betablockers, on calcium antagonists was shown experimentally to promote the initiation and on lipid lowering drugs. and progression of atherosclerosis by its proinflammatory and pro-coagulatory actions. In accordance with this notion, epidemiologial evidence associ-What was found?
ated activation of the RAS with a higher prevalence of atherosclerotic complications in hypertensive Vitamin E was without any effect on outcomes. On patients [3, 4] . Obviously, ACE inhibitors interfere also Ramipril, a total of 653 (14.1%) patients reached a with kinins. It is therefore entirely possible that stimu-primary end-point and 824 (17.7%) on placebo (relative lation of bradykinin contributes to the effects of ACE risk, RR, 0.78, P<0.001). Ramipril significantly inhibitors [5] .
(P<0.01) reduced myocardial infarction (9.9 vs The HOPE study tested the hypothesis that inhibi-12.2%), cardiovascular death (6.1 vs 8.1%), stroke (3.4 tion of the RAS and stimulation of bradykinin by the vs 4.9%), revascularization procedures (16.0 vs 18.6%), ACE inhibitor Ramipril would reduce cardiovascular and diabetic complications (6.2 vs 7.4%, P=0.03). events in patients at high cardiovascular risk-includ-Unexpectedly, diabetes mellitus was diagnosed de novo ing predominately normotensive patients [6] [7] [8] [9] . The during the trial less frequently in patients on Ramipril ambition to go from experimental evidence to clinical (n=105) than in patients on placebo (n=154, relative investigation was prompted by the success of ACE risk 0.68, P=0.002). The major problem associated inhibitor treatment in patients with reduced left ventri-with Ramipril was a 5% rate of cough. It appeared cular function [10] . In the latter patients the ACE that the relative benefit of Ramipril became greater inhibitors, unexpectedly, appeared to reduce not only with time and was evident in all pre-defined subgroups. the frequency of cardiac failure but also the rate of Such groups included hypertensive (47% of the populamyocardial infarction [10] . tion), diabetic (38%), male and female patients (26%), those with microalbuminuria (21%) and those without known cardiovascular disease. Treating 1000 patients
What was done?
for 4 years would prevent about 150 major events in 70 people. The small but significant blood pressure More than 9000 patients at high cardiovascular risk, lowering effects of Ramipril by about 3/2 mm Hg could 55 years of age or more, with (i) evidence of vascular not fully explain the beneficial effects of the drug in disease or with (ii) diabetes plus one other cardiovas-these patients most of whom were treated by other cular risk factor were followed for 4-6 years [6 ] . Heart drugs. failure and low ejection fraction were major exclusion criteria. In a double-blind, randomized, placebocontrolled 2×2 factorial design, Ramipril (up to How do the results affect patient management by 10 mg/day) and vitamin E (400 U/day) were tested. the nephrologist?
